Literature DB >> 34435331

Neuropsychiatric Manifestations of Wilson Disease: Correlation with MRI and Glutamate Excitotoxicity.

Jayantee Kalita1, Vijay Kumar2, Vasudev Parashar3, Usha K Misra4.   

Abstract

This study aims to identify neuropsychiatric manifestations in neurological Wilson disease (NWD), and their correlation with MRI changes and glutamate excitotoxicity. Forty-three consecutive patients with NWD from a tertiary care teaching hospital were evaluated prospectively who fulfilled the inclusion criteria. The neuropsychiatric evaluation was done using Neuropsychiatric Inventory (NPI) battery that assesses 12 domains including delusion, hallucination, agitation/aggression, dysphoria/depression, anxiety, euphoria, apathy, disinhibition, irritability, aberrant motor activity, appetite change, and abnormal nighttime behavior. Cranial MRI was done using a 3 T machine, and locations of signal changes were noted including the total number of MRI lesions. Serum glutamate level was measured by a fluorescence microplate reader. Abnormal NPI in various domains and total NPI scores were correlated with MRI lesions, serum and urinary copper, and glutamate level. The median age of the patients was 16 years. Forty-one (48.8%) patients had cognitive impairment and 37 (86%) had movement disorder. Neurobehavioral abnormality was detected in all-commonest being agitation (90.7%) followed by appetite change (81.4%), elation (74.4%), irritability (69.8%), anxiety (67.4%), depression (65.1%), apathy (44.2%), night time abnormal behavior (32.6%), aberrant motor behavior (20.9%), delusions (16.3%), and hallucination (18.6%). The thalamic lesion was associated with depression, globus pallidus with depression and anxiety, caudate with anxiety and agitation, brainstem with irritability, and frontal cortex with apathy. Serum glutamate level was higher in NWD. NPI sum score correlated with MRI load and glutamate level. Varying severity of neurobehavioral abnormalities are common in the patients with NWD and correlate with the location of MRI lesion and glutamate level.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Anxiety; Delusion; Depression; Glutamate; Hallucination; Irritability; MRI; Wilson disease; Copper; Neuropsychiatric inventory

Mesh:

Substances:

Year:  2021        PMID: 34435331     DOI: 10.1007/s12035-021-02525-4

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  57 in total

1.  A study of MRI changes in Wilson disease and its correlation with clinical features and outcome.

Authors:  A Ranjan; J Kalita; S Kumar; S K Bhoi; U K Misra
Journal:  Clin Neurol Neurosurg       Date:  2015-07-21       Impact factor: 1.876

Review 2.  Regional distribution of mutations of the ATP7B gene in patients with Wilson disease: impact on genetic testing.

Authors:  Peter Ferenci
Journal:  Hum Genet       Date:  2006-06-22       Impact factor: 4.132

Review 3.  Wilson disease.

Authors:  Anna Członkowska; Tomasz Litwin; Petr Dusek; Peter Ferenci; Svetlana Lutsenko; Valentina Medici; Janusz K Rybakowski; Karl Heinz Weiss; Michael L Schilsky
Journal:  Nat Rev Dis Primers       Date:  2018-09-06       Impact factor: 52.329

4.  The Prevalence of Wilson's Disease: An Update.

Authors:  Thomas Damgaard Sandahl; Tea Lund Laursen; Ditte Emilie Munk; Hendrik Vilstrup; Karl Heinz Weiss; Peter Ott
Journal:  Hepatology       Date:  2020-01-31       Impact factor: 17.425

5.  MR Imaging of the Brain in Neurologic Wilson Disease.

Authors:  X-E Yu; S Gao; R-M Yang; Y-Z Han
Journal:  AJNR Am J Neuroradiol       Date:  2019-01       Impact factor: 3.825

6.  Diagnosis of Wilson's disease: an experience over three decades.

Authors:  P J Gow; R A Smallwood; P W Angus; A L Smith; A J Wall; R B Sewell
Journal:  Gut       Date:  2000-03       Impact factor: 23.059

Review 7.  Psychiatric and behavioral abnormalities in Wilson's disease.

Authors:  M Akil; G J Brewer
Journal:  Adv Neurol       Date:  1995

8.  Dominant psychiatric manifestations in Wilson's disease: a diagnostic and therapeutic challenge!

Authors:  K Srinivas; S Sinha; A B Taly; L K Prashanth; G R Arunodaya; Y C Janardhana Reddy; S Khanna
Journal:  J Neurol Sci       Date:  2007-09-27       Impact factor: 3.181

9.  The Wilson disease gene: spectrum of mutations and their consequences.

Authors:  G R Thomas; J R Forbes; E A Roberts; J M Walshe; D W Cox
Journal:  Nat Genet       Date:  1995-02       Impact factor: 38.330

Review 10.  Psychiatric manifestations in Wilson's disease: possibilities and difficulties for treatment.

Authors:  Tomasz Litwin; Petr Dusek; Tomasz Szafrański; Karolina Dzieżyc; Anna Członkowska; Janusz K Rybakowski
Journal:  Ther Adv Psychopharmacol       Date:  2018-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.